FDA approves updated WINREVAIR label for HYPERION trial data
Merck said the U.S. FDA approved an update to the U.S. label for WINREVAIR (sotatercept-csrk) for injection (45mg, 60mg) based on Phase 3 HYPERION trial data in adults recently diagnosed with pulmonary arterial hypertension (PAH, WHO Group 1).